Trial Condition(s):

Arthritis, Rheumatoid

BAY1830839: First in Man, single dose escalation, safety & tolerability and pharmacokinetics

Bayer Identifier:

19150

ClinicalTrials.gov Identifier:

NCT03540615

EudraCT Number:

2017-001496-23

Study Completed

Trial Purpose

The primary objectives of this study are to investigate
•    the safety and tolerability of increasing single oral doses of BAY 1830839 versus placebo under fasted conditions
•    the pharmacokinetics after single ascending oral doses of BAY 1830839 under fasted conditions

Inclusion Criteria
- Body mass index (BMI) : ≥18.5 and ≤30 kg/m*2
Exclusion Criteria
- Relevant diseases within the last 4 weeks prior to the first study drug administration
 -  Febrile illness within 4 weeks before the first study drug administration
 - Known hypersensitivity to the study drugs or components of the preparations
 - Clinically relevant findings in the physical examination

Trial Summary

Enrollment Goal
64
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
Yes
Products
BAY1830839
Accepts Healthy Volunteers
Yes

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

CRS Clinical Research Services Berlin GmbH

Berlin, Germany, 13353

Status
Completed
 

Trial Design